---

備註請放最後面 違者新聞文章刪除

1.媒體來源: Reuters
※ 例如蘋果日報、自由時報（請參考版規下方的核准媒體名單）


2.記者署名: Francesco Guarascio

※ 若新聞沒有記者名字或編輯名字，請勿張貼，否則會被水桶14天
※ 外電至少要有來源或編輯 如:法新社


3.完整新聞標題:
EU seals deal with Novavax for up to 200 million COVID-19 vaccines

※ 標題沒有完整寫出來 ---> 依照板規刪除文章


4.完整新聞內文:
BRUSSELS, Aug 4 (Reuters) - The European Commission has approved a supply
contract with U.S. firm Novavax (NVAX.O)to buy up to 200 million doses of its
potential COVID-19 vaccine, the Commission said on Wednesday.

The move is part of the EU's strategy to diversify its vaccine portfolio
after the bloc betted heavily for the coming years on messenger RNA (mRNA)
shots produced by Pfizer-BioNTech (PFE.N), (22UAy.DE) and Moderna (MRNA.O).

"Our new agreement with Novavax expands our vaccine portfolio to include one
more protein-based vaccine, a platform showing promise in clinical trials,"
EU health commissioner Stella Kyriakides said in a statement.

French drugmaker Sanofi (SASY.PA), in partnership with British firm
GlaxoSmithKline (GSK.L), is also trying to produce a protein-based COVID-19
vaccine and has already signed a supply deal with the EU. But their trials
suffered a setback in December, delaying development.

Under the contract, EU states will be able to buy up to 100 million doses of
the Novavax vaccine, with an option for 100 million additional doses until
2023, once the shot has been approved by the EU drugs regulator which is
currently reviewing it, the Commission said.

Novavax reached a preliminary deal with the bloc in December, but a final
agreement was delayed for months because the U.S. company faced productions
problems read more .

The deal would allow EU states to receive the first Novavax doses from the
last quarter of this year, the Commission said, confirming a Reuters report
from May read more

Novavax confirmed the deal in a statement and said it was working to complete
the submission of vaccine data to the EU drugs regulator in the third quarter
of this year, with delivery of initial doses expected to begin after approval.

"As new coronavirus variants are spreading in Europe and around the world,
this new contract with a company that is already testing its vaccine
successfully against these variants is an additional safeguard for the
protection of our population," European Commission President Ursula von der
Leyen said.

The EU has reserved a total of 2.4 billion doses of the Pfizer-BioNTech
vaccine in three different contracts, and has also bought 460 million Moderna
shots, clear signs of its preference for mRNA jabs.

It has also booked 405 million doses of the mRNA vaccine developed by CureVac
(5CV.DE), although the vaccine has so far shown limited efficacy in tests and
has not yet been approved by regulators.

The bloc also has supply deals with AstraZeneca (AZN.L) and Johnson & Johnson
(JNJ.N) which both produce viral vector vaccines against COVID-19, but the EU
has reduced its reliance on these shots after health concerns and supply
problems.

Novavax is the seventh company with which the EU has signed a supply deal for
COVID-19 vaccines.

歐盟執委會已批准 購買至多兩億劑的Novavax潛在疫苗
一旦疫苗完成審核 預計可於今年第四季開始交貨給歐洲國家
Novavax表示會於第三季完成向歐盟監管機構提供資料
目前為止 歐盟共訂購了24億劑Pfizer-BioNTech 疫苗 4.6億劑Moderna疫苗
4.05億劑CureVac疫苗(尚未通過審核)
也有與AstraZeneca, Johnson & Johnson達成供應協議
Novavax是第七間與歐盟簽訂COVID-19疫苗供應協定的公司

※ 社論特稿都不能貼！違者刪除（政治類水桶3個月)，貼廣告也會被刪除喔！可詳看版規


5.完整新聞連結 (或短網址):https://reut.rs/3rYQf7G
※ 當新聞連結過長時，需提供短網址方便網友點擊


6.備註:
※ 一個人三天只能張貼一則新聞，被刪或自刪也算額度內，超貼者水桶，請注意
※ 備註請勿張貼三日內新聞(包含連結、標題等)


--
給酷~ 給酷~ 給..給酷 給酷 給....啊!!!! 為什麼...為什麼不幫我發大絕極靈~~~~~ (斗
內:果然牛逼反觀斗基督機大神) 啊!!墮!!　啊!!! Double kill!! 巨槌瑞斯 誇爪~~ 哈哈
哈~哈哈哈哈!! 恩ㄣㄣㄣㄣ(轉手 哇!～還敢下來R冰鳥～～　哇!老爸墮起來~Double kill~
哈哈哈~哈哈哈哈哈哈!! 哇! 哇~嬰兒! 哇! Double kill! 達瑞斯~~~ LALALALALALALALALA
~LALALALA!!!不要不要不要不要不要不要... 有囉！這波有囉~ 哈薩KI!吹起來!聊天室滑起
來!滑起來!!! Death is like the wind always by my side亞索開滑~~ WooWooWooWoo賀賀

--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 218.35.146.170 (臺灣)
※ 文章代碼(AID): #1X3CogMo (Gossiping)
※ 文章網址: https://www.ptt.cc/bbs/Gossiping/M.1628228778.A.5B2.html